

Med Klin Intensivmed Notfmed 2019 · 114:724–732  
<https://doi.org/10.1007/s00063-018-0477-z>  
 Received: 10 January 2018  
 Revised: 27 May 2018  
 Accepted: 8 July 2018  
 Published online: 21 August 2018  
 © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

## Redaktion

M. Buerke, Siegen



M. Müller<sup>1</sup> · J. C. Schefold<sup>2</sup> · A. B. Leichtle<sup>3</sup> · D. Srivastava<sup>1</sup> · G. Lindner<sup>4</sup> · A. K. Exadaktylos<sup>1</sup> · C. A. Pfortmueller<sup>2</sup>

<sup>1</sup> Department of Emergency Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>2</sup> Department of Intensive Care, Inselspital, Bern University Hospital, Bern, Switzerland

<sup>3</sup> Department of Clinical Chemistry, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

<sup>4</sup> Department of Emergency Medicine and General Internal Medicine, Hirslandenlinik am Park, Zurich, Switzerland

# qSOFA score not predictive of in-hospital mortality in emergency patients with decompensated liver cirrhosis

## Introduction

In February 2016 the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) were published and a new clinical score named quick Sequential Organ Failure Assessment (qSOFA) was presented [1]. The score contains a set of three variables (respiratory rate, mental status, systolic blood pressure) and was proposed as a bedside screening tool for patients with suspected sepsis [1]. Several studies have assessed the utility of qSOFA for prediction of outcome in the intensive care unit (ICU) and emergency department (ED) setting in patients with suspected sepsis [2–13]. qSOFA has also shown a good predictive value for adverse outcomes (ICU admission, length of hospitalisation, mortality) in the general ED and ICU population [14]. However, further validations in respective subgroups of ED patients with a high mortality have not yet been performed.

Liver cirrhosis was the eighth leading cause of death in the United States in 2010 [15] and has accounted for over a million deaths worldwide with a rising incidence over the last 30 years [16]. Admissions to hospitals due to liver cirrhosis are associated with an overall in-hospital mortality of about 8% [17] which increases to

35% in patients with decompensated liver cirrhosis [18]. Patients with decompensated liver cirrhosis show typical haemodynamic and pathophysiological changes [19] which have some similarity to sepsis [20], including alterations in mental status due to development of hepatic encephalopathy [19, 21]. It seems therefore probable that the use of qSOFA may help to distinguish patients with adverse outcomes from the ones with a favourable course in decompensated liver cirrhosis.

We therefore aimed to validate the prognostic performance of qSOFA in patients presenting with decompensated liver cirrhosis for the primary outcome of in-hospital mortality. Secondly, we evaluated whether the use of qSOFA adequately predicts ICU admission and length of hospitalisation and compared its predictive value to other disease severity markers such as systemic inflammatory response syndrome (SIRS), model of end stage liver disease score (MELD) and Child–Pugh score. In addition, we tested whether a disease-specific alteration of qSOFA by extension with a point for hyponatraemia increases its prognostic performance.

## Methods

### Setting

The study site was the emergency department (ED) of Bern University Hospital (Inselspital), which is one of the largest hospitals in Switzerland with a catchment area of about 2 million people in the Canton Bern, Switzerland.

### Data collection and eligibility criteria

All medical records of all adult patients admitted to our ED between January 1, 2002 and December 31, 2012 were screened with a keyword search of “decompensated liver cirrhosis” with different semantic combinations in the diagnosis or medical history field of our computerised patient database (Qualicare Office, Medical Database Software; Qualidoc AG, Bern, Switzerland). All patients older than 16 years with a primary diagnosis of decompensated liver cirrhosis were considered eligible for inclusion. Only the first presentation with decompensated liver cirrhosis was included in the analysis in case of multiple admissions. Exclusion criteria were as follows: lack of parameters for calculation of the qSOFA score, double

Table 1 Patient characteristics		
Characteristics		
<i>n</i> <sup>a</sup>	186	(100.0)
Sex, <i>n</i> (%)		
Male	137	(73.7)
Female	49	(26.3)
Age (years), median (IQR)	57	(52–66)
Aetiology of cirrhosis, <i>n</i> (%)		
Alcohol	92	(49.5)
Alcohol and hepatitis B	1	(0.5)
Alcohol and hepatitis B and C	7	(3.8)
Alcohol and hepatitis C	38	(20.4)
Hepatitis B	12	(6.5)
Hepatitis B and C	4	(2.2)
Hepatitis C	20	(10.8)
Hemochromatosis	2	(1.1)
Alpha-1-antitrypsin deficiency	2	(1.1)
Unknown	8	(4.3)
Child–Pugh classification, <i>n</i> (%)		
A	17	(9.1)
B	55	(29.6)
C	102	(54.8)
Unknown	12	(6.5)
Hepatocellular carcinoma, <i>n</i> (%)	26	(14.0)
Signs of decompensation, <i>n</i> (%)		
Ascites	94	(50.5)
Bleeding	52	(28.0)

entries in our database, patients with chronic decompensated liver cirrhosis, or any other primary reason for ED admission (e.g. trauma). Our study comprises a subset of patients of an already published cohort [22].

## Data extraction

Sociodemographic (age, gender), clinical data (aetiology of liver cirrhosis, clinical signs of decompensation such as ascites, haemorrhage, encephalopathy, jaundice, hepatorenal syndrome, vital parameters [first value within an hour from admission], coexistence of hepatocellular carcinoma, concurrent diagnosis of spontaneous bacterial peritonitis), laboratory parameters as well as administrative data (intensive care unit [ICU] admissions, length of hospitalisation, and in-hospital mortality) were

Table 1 (Continued)		
Characteristics		
Hepatorenal syndrome	57	(30.7)
Encephalopathy	101	(54.3)
Jaundice	47	(25.3)
Spontaneous bacterial peritonitis <sup>b</sup> , <i>n</i> (%)	14	(7.5)
ACLF ( <i>n</i> = 159), <i>n</i> (%)	37	(23.3)
CLIF-C AD score ( <i>n</i> = 181), median (IQR)	53.5	(47–61)
MELD score ( <i>n</i> = 147), median (IQR)	15	(11–20)
SIRS ( <i>n</i> = 159), <i>n</i> (%)		
<2	104	(65.4)
≥2	55	(34.6)
qSOFA, <i>n</i> (%)		
<2	164	(88.2)
≥2	22	(11.8)
qSOFA-Na+ ( <i>n</i> = 183), <i>n</i> (%)		
<2	36	(19.7)
≥2	147	(80.3)
qSOFA quick sequential organ failure assessment, SIRS systemic inflammatory response syndrome, MELD model of end stage liver disease score		
<sup>a</sup> if not indicated otherwise		
<sup>b</sup> A paracentesis was performed in 46 (24.7%) patients		

analysed. From the available data the Child–Pugh score, the Model of End Stage Liver Disease (MELD) score, the Systemic Inflammatory Response Syndrome (SIRS) criteria, CLIF-C AD score [23] and the qSOFA score were calculated. Additionally, the proportion of patients suffering from acute on chronic liver failure (ACLF) was determined.

## Definitions

### qSOFA

qSOFA was defined according to the Surviving Sepsis Campaign 2016 [1]. Patients were attributed 1 point for a Glasgow Coma Scale (GCS) of 14 or less, 1 point for a systolic blood pressure of 100 mm Hg or less and respiration rate of 22/min or more.

### qSOFA-Na+

Hyponatraemia (defined as 130 mmol/l or lower) in patients with decompensated liver cirrhosis has been linked to increased disease severity and mortality

[24–26]. The qSOFA was increased by one point for a serum sodium at ED admission of ≤130 mmol/l.

## Acute on chronic liver failure

The definitions for acute on chronic liver failure (ACLF) are very heterogeneous and still subject to much discussion [27]. We used a modified version of the CLIF-C ACLF score, a cumulative score for organ failure to define ACLF, to assess for ACLF. Patients with liver failure that *did not* fulfil one of the following three criteria were considered to have ACLF: (i) no organ failure, (ii) one organ failure (liver coagulation, circulatory, or respiratory) with creatinine <1.5 mg/dL and no hepatic encephalopathy (any grade), (iii) single cerebral failure and creatinine <1.5 mg/dL. In accordance with the CLIF-C ACLF, liver failure was defined as bilirubin levels above 12 mg/dL, and coagulation failure as an INR above 2.5 [28]. The definitions of brain failure, circulatory compromise and respiratory failure were modified as follows: brain failure was defined as the presence of hepatic encephalopathy (any grade), circulation failure as a systolic blood pressure below 90 mm Hg and respiratory failure as SpO<sub>2</sub> levels of below 90%.

### CLIF-C AD score

A linear combination of age, sodium levels and the logarithms of INR and white blood cells are used to calculate the score [23]. For the purpose of this study, we calculated the CLIF-C AD as a severity marker of the decompensation for all patients independently of the presence of ACLF.

### Threshold values

qSOFA, qSOFA-Na+ and SIRS criteria were considered positive when the patient scored two or more points [1]. A MELD score of 25 or higher was considered to be high, where as a MELD score of 24 or lower was considered low [30]. A CLIF-C AD score of 44 or below was defined as low-risk acute decompensation [29].

Med Klin Intensivmed Notfmed 2019 · 114:724–732 <https://doi.org/10.1007/s00063-018-0477-z>  
© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

M. Müller · J. C. Schefold · A. B. Leichtle · D. Srivastava · G. Lindner · A. K. Exadaktylos · C. A. Pfortmueller

## qSOFA score not predictive of in-hospital mortality in emergency patients with decompensated liver cirrhosis

### Abstract

**Background.** Quick sequential organ failure assessment (qSOFA) has been validated for patients with presumed sepsis and the general emergency department (ED) population. However, it has not been validated in specific subgroups of ED patients with a high mortality. We aimed to investigate the prognostic performance of qSOFA with respect to in-hospital mortality, intensive care unit (ICU) admission, and length of hospitalisation in patients with decompensated liver cirrhosis. Furthermore, we compared qSOFA to systemic inflammatory response syndrome (SIRS), model of end stage liver disease score (MELD), and Child–Pugh criteria and evaluated whether addition of sodium ( $\text{Na}^+$ ) levels to qSOFA increases its prognostic performance.

**Methods.** This observational study included patients admitted with the diagnosis of decompensated liver cirrhosis. All patients with a complete set of vital parameters were included in this study.

**Results.** A total of 186 patients were included. A positive qSOFA score was not associated with in-hospital mortality, ICU admission, or length of hospitalisation (all  $p > 0.15$ ). MELD scores reliably predicted need for ICU admission and in-hospital mortality (both  $p < 0.01$ ), but not the length of hospitalisation. qSOFA- $\text{Na}^+$  only moderately increased the diagnostic performance of qSOFA with regard to need for ICU admission ( $\text{AUC}_{\text{ICU}}[\text{qSOFA}] = 0.504$  vs.  $\text{AUC}_{\text{ICU}}[\text{qSOFA-}\text{Na}^+] = 0.609$ ,  $p = 0.03$ ), but not for in-

hospital mortality ( $\text{AUC}_{\text{death}}[\text{qSOFA}] = 0.513$  vs.  $\text{AUC}_{\text{death}}[\text{qSOFA-}\text{Na}^+] = 0.592$ ,  $p = 0.054$ ).

**Conclusion.** qSOFA does not predict in-hospital mortality, ICU admission or length of hospitalisation in patients with decompensated liver cirrhosis. Extension of qSOFA with a disease-specific component, the qSOFA- $\text{Na}^+$ , moderately increased the diagnostic ability of qSOFA.

### Keywords

Mortality prediction · Emergency admissions · Critical illness · QSOFA extended · Electrolyte disorder · Sodium

## qSOFA-Score nicht prädiktiv für Krankenhaussterblichkeit bei Notfallpatienten mit dekompensierter Leberzirrhose

### Zusammenfassung

**Hintergrund.** Der „quick sequential organ failure assessment“ (qSOFA)-Score wurde zur Prädiktion der Mortalität sowohl bei Patienten mit Verdacht auf Sepsis als auch bei Notfallpatienten im Allgemeinen validiert. Eine Validierung bei bestimmten Untergruppen von Notfallpatienten mit hoher Mortalität ist jedoch noch nicht erfolgt. Ziel dieser Arbeit war es, die prognostische Wertigkeit bei Patienten, die sich mit dekompensierter Leberzirrhose in der Notaufnahme vorstellen, in Bezug auf Krankenhaussterblichkeit, Verlegung auf die Intensivstation und Krankenhausverweildauer zu analysieren. Des Weiteren wurde qSOFA mit „systemic inflammatory response syndrome“ (SIRS)-, „model of end stage liver disease score“ (MELD)- und Child–Pugh-Kriterien verglichen. Es wurde überprüft, ob die Einbeziehung des Natriumspiegels ( $\text{Na}^+$ ) in qSOFA die prognostische Wertigkeit erhöht.

**Methoden.** Alle Patienten mit der Aufnahme­diagnose einer dekompensierten Leberzirrhose, die sich über einen Zeitraum von 10 Jahren in der Notaufnahme des Universitätsklinikums Bern, Schweiz, vorstellten, wurden in die Beobachtungsstudie eingeschlossen. Die Dokumentation der Vitalparameter musste vollständig sein.

**Ergebnisse.** In die Studie wurden 186 Patienten eingeschlossen. Der MELD-Score war sowohl mit der Krankenhaussterblichkeit als auch mit der notfallmäßigen Verlegung auf die Intensivstation assoziiert (je  $p < 0,01$ ), nicht jedoch mit der Krankenhausverweildauer. Ein positiver qSOFA-Score ( $\geq 2$  Punkte) war dagegen nicht mit der Krankenhaussterblichkeit, Verlegung auf die Intensivstation oder Krankenhausverweildauer assoziiert (je  $p > 0,15$ ). Eine Erweiterung des qSOFA-Scores um die Natriumkomponente (qSOFA- $\text{Na}^+$ ) erhöhte die Vorhersagekraft bezüglich

der notfallmäßigen Verlegung auf die Intensivstation moderat ( $\text{AUC}[\text{qSOFA}] = 0,504$  vs.  $\text{AUC}[\text{qSOFA-}\text{Na}^+] = 0,609$ ,  $p = 0,03$ ), die bezüglich der Krankenhaussterblichkeit dagegen nicht ( $\text{AUC}[\text{qSOFA}] = 0,513$  vs.  $\text{AUC}[\text{qSOFA-}\text{Na}^+] = 0,592$ ,  $p = 0,054$ ).

**Schlussfolgerung.** Der qSOFA-Score besitzt keine ausreichende Vorhersagekraft für die Krankenhaussterblichkeit, notfallmäßige Verlegung auf die Intensivstation oder Krankenhausverweildauer bei Patienten mit dekompensierter Leberzirrhose. Eine Erweiterung des qSOFA-Scores um eine erkrankungsspezifische Natriumkomponente erhöht die prognostische Wertigkeit moderat.

### Schlüsselwörter

Mortalitätsprädiktion · Notfallzuweisungen · Kritische Erkrankung · Erweiterter qSOFA-Score · Elektrolytstörung · Natrium


### Ethical considerations

The study was approved by the regional ethics committee of the Canton of Bern, Switzerland (KEK: 14-02-13). Individual informed consent was waived by the ethics committee.

### Statistical analysis

Statistical analysis was performed using Stata<sup>®</sup> 13.1 (StataCorp, College Station, TX, USA). Interval variables are presented as medians with 25th–75th interquartile ranges (IQR). For categorical variables, the total number and

respective proportions are given. Comparisons of interval variables between qSOFA-positive and qSOFA-negative groups were performed using the Mann–Whitney U test, and Kruskal–Wallis analysis of variance with post hoc testing using the Mann–Whitney U test. Comparisons of categorical variables



**Fig. 1** ▲ CONSORT flow chart. *qSOFA* quick Sequential Organ Failure Assessment

between the *qSOFA*-positive and the *qSOFA*-negative group were performed by Fisher's exact test. Predictive value of SIRS, MELD, Child–Pugh score and *qSOFA*-Na<sup>+</sup> were analysed as described for *qSOFA*. To compare the diagnostic performance of *qSOFA* and *qSOFA*-Na<sup>+</sup> with regard to in-hospital mortality and need for ICU admission, the equality of the area under the receiver operating curves (AUC) was tested using the *roccomp* command [31]. A *p*-value of <0.05 was considered as significant.

## Results

### Patients' demographics

One hundred eighty-six (186) patients were eligible for study inclusion. The CONSORT flow chart is given in **Fig. 1**. The study population consists of 73.7% male patients with a median age of 57 years (IQR 52–66). Patient characteristics are given in **Table 1**. The most common aetiology of liver cirrhosis was chronic alcohol consumption (*n*=92, 49.5%) followed by of chronic alcohol consumption and hepatitis B

infection (*n* = 38, 20.4%) and hepatitis C infection (*n* = 20, 10.8%). The median MELD score was 15.1 (IQR 10.8–19.9) and Child–Pugh score C was the most common stage of liver cirrhosis (*n* = 102, 54.8%). A total of 65 patients (35.0%) were admitted to the ICU and 29 patients (15.6%) died in the hospital. The median duration of hospitalisation was 8 days (IQR 3–14). The percentage of ACLF was 23.3% (*n* = 37), the median CLIF-C AD score was 54 (IQR 47–61). Of patients with ACLF 54.1% (*n* = 20) were admitted to the ICU, the median length of hospitalisation was 11 days (IQR 2–20) and 35.1% (*n* = 13) of the patients died.

### *qSOFA* assessment including *qSOFA*-Na<sup>+</sup>

The *qSOFA* score was positive in 22 patients (11.8%). Patients with a positive *qSOFA* score did not differ significantly with respect to age, aetiology of liver cirrhosis, Child–Pugh classification and MELD score from patients with a negative *qSOFA* score (*p* = 0.145, *p* = 0.770,

*p* = 0.880, respectively *p* = 0.098, see **Table 2**).

With respect to our primary and secondary study outcomes the *qSOFA* score did not discriminate between survivors and nonsurvivors (*p* = 0.755), ICU admissions (*p* = 0.152) and length of hospitalisation (*p* = 0.489). For a comparison between SIRS, Child–Pugh classification, MELD, ACLF, CLIF-C AD and *qSOFA* with respect to our study outcomes, see **Table 3**. The MELD score was the only established score to reliably predict ICU admissions (*p* = 0.007) and in-hospital mortality (*p* = 0.003) in our patient collective, but not the length of hospitalisation (*p* = 0.266).

To test whether the addition of sodium to the *qSOFA* score would increase its predictive power the *qSOFA*-Na<sup>+</sup> score was calculated. *qSOFA*-Na<sup>+</sup> was significantly associated with in-hospital mortality (*p* = 0.038) and ICU admission (*p* = 0.001), but not with length of hospitalisation (*p* = 0.266; see **Table 3**). The sensitivity and negative predictive value for both (a) ICU admission and (b) in-hospital mortality was increased in *qSOFA*-Na<sup>+</sup> compared to *qSOFA* without a notable decrease in specificity and positive predictive value (a) ICU admission: sensitivity: 0.344 vs. 0.169, specificity: 0.875 vs. 0.909, positive predictive value: 0.595 vs. 0.500, negative predictive value: 0.714 vs. 0.671; (b) in-hospital: sensitivity: 0.357 vs. 0.138, specificity: 0.827 vs. 0.885, positive predictive value: 0.270 vs. 0.182, negative predictive value: 0.878 vs. 0.848. The addition of sodium to *qSOFA* increased its diagnostic performance with regard to ICU admissions (AUC<sub>ICU</sub> *qSOFA* = 0.504 vs. AUC<sub>ICU</sub> *qSOFA*-Na<sup>+</sup> = 0.609, *p* = 0.006), but not with respect to in-hospital mortality (AUC<sub>death</sub> *qSOFA*: 0.513 vs. AUC<sub>death</sub> *qSOFA*-Na<sup>+</sup>: 0.592, *p* = 0.054, see **Fig. 2**). Adjusting the cut-off for *qSOFA*-Na<sup>+</sup> to 1 point for a sodium level of 125 mmol/l and below, or 120 mmol/l and below did not increase its diagnostic ability (see **Fig. 3**).

**Table 2** Comparison of qSOFA-positive and qSOFA-negative patients

Characteristics	qSOFA < 2		qSOFA ≥ 2		p
n <sup>a</sup>	164	(100.0)	22	(100.0)	–
Sex, n (%)					
Male	120	(73.2)	17	(77.3)	–
Female	44	(26.8)	5	(22.7)	0.801
Age years, median (IQR)	57	(51–66)	60.5	(54–65)	0.145
Aetiology of cirrhosis, n (%)	–	–	–	–	0.770
Child–Pugh classification, n (%)	–	–	–	–	0.880
Hepatocellular carcinoma, n (%)	–	–	–	–	0.519
Signs of decompensation, n (%)					
Ascites	85	(51.8)	9	(40.9)	0.371
Bleeding	47	(28.7)	5	(22.7)	0.801
Hepatorenal syndrome	48	(29.3)	9	(40.9)	0.325
Encephalopathy	88	(53.7)	13	(59.1)	0.657
Jaundice	44	(26.8)	3	(13.6)	0.294
ACLIF (n = 158), n (%)	29	(20.6)	8	(44.4)	0.024
CLIF-C AD score (n = 181), median (IQR)	52.7	(47–60)	57.1	(53–70)	0.019
MELD score (n = 147), median (IQR)	15	(11–20)	18	(15–23)	0.098
Length of hospitalisation, median (IQR)	7.0	(3–13)	8.5	(2–21)	0.489
ICU admission, n (%)	54	(32.9)	11	(50.0)	0.152
In-hospital mortality, n (%)	25	(15.2)	4	(18.2)	0.755

qSOFA quick sequential organ failure assessment, ICU intensive care unit, MELD model of end stage liver disease score

<sup>a</sup> if not indicated otherwise

## Discussion

We present the first study investigating qSOFA in patients with decompensated liver cirrhosis. Despite the similarity in haemodynamic and pathophysiological features to sepsis, qSOFA does not predict mortality, ICU admissions or length of hospitalisation in patients with decompensated liver cirrhosis.

Several studies showed that the qSOFA score is a valuable predictor for in-hospital mortality and length of hospitalisation in patients presenting with suspected infection [2, 5, 6, 12, 14, 32] as well as for the general adult ED patient collective [14]. Whether qSOFA adequately predicts ICU admission in ED patients with suspected sepsis remains controversial [5, 6, 12, 14]. While some studies showed a clear association of qSOFA with ICU admissions [6, 14], others could not confirm these findings [5, 12]. In our study qSOFA was not associated with either in-hospital mortality, ICU admission, or length of hospitalisation. This may highlight that the predictive perfor-

mance shown for the general adult ED population [14] may not be applicable to a specific subgroup of ED patients. Our hypothesis that the distinct physiological changes in patients with decompensated liver cirrhosis may share a certain similarity to sepsis and therefore qSOFA might have a similar predictive ability remains unconfirmed. Thus, it is possible that the change in mental state due to hepatic encephalopathy may not as gravely influence outcome as the mental alteration in patients with sepsis. This is underlined by the small percentage of patients with spontaneous bacterial peritonitis in our sample when compared to others [33, 34] and therefore the haemodynamic changes and mental alterations probably are mostly attributed to the decompensated liver disease and not due to infection in our study.

In addition, our study sample size is quite small and the predictive ability of qSOFA with regard to our study outcomes may not have become statistically significant. However, our sample had a similar length of hospitalisation and in-hospital

mortality rates as others [17, 35, 36], and may therefore well be representative for patients with decompensated liver cirrhosis.

Amongst the already established outcome scores for patients with decompensated liver cirrhosis evaluated in our study, only the MELD score was associated with in-hospital mortality and ICU admission. This finding is not surprising as the MELD score is a highly disease-specific score that was developed to predict mortality in patients after transjugular portosystemic shunt [30] and has been validated for patients with decompensated liver cirrhosis in various studies [37–39]. In addition, it has been shown that qSOFA might not be superior when compared to “conventional” outcome scores such as APACHE II or Charlson Comorbidity index for prediction of mortality in patients with sepsis [6, 8, 40].

Surprisingly, however positive SIRS criteria were not associated with in-hospital mortality or ICU admission in our study. Positive SIRS score was clearly linked to outcome in patients with decompensated liver cirrhosis by others [41–43] and was equally predictive when compared to the MELD score [43]. On the other hand, a recently published study by Piano and co-workers demonstrated that qSOFA and sepsis-3 criteria were significantly better prognostic factors with respect to mortality than SIRS in patients with decompensated liver cirrhosis and bacterial infections [44]. However, in this trial only patients with a proven or highly suspected bacteria/fungal infection were included and not the general patient presenting with decompensated liver cirrhosis as in our study. Thus, qSOFA seems to be an insufficient screening tool in the overall patient collective with decompensated liver cirrhosis, but may have some strength in patients with decompensated liver cirrhosis and proven infection.

The failure of positive SIRS criteria to adequately predict outcomes in this study is surprising for another reason. Several studies have shown that SIRS criteria are more sensitive, thus less specific than qSOFA [6, 7, 11, 45]; therefore we would



**Table 3** Comparison of qSOFA with other outcome scores in patients with decompensated liver cirrhosis

	No.	Length of hospitalisation (days)			ICU Admission			In-hospital mortality		
		Median (IQR)		<i>p</i>	Frequency (%)	<i>p</i>	Frequency (%)	<i>p</i>		
<i>MELD</i> <sup>a</sup>										
<25	143	7.0	(3–13)	0.621	45 (31.5)	0.007	18 (12.6)	0.003		
≥25	22	11.5	(3–18)		14 (63.6)		9 (40.9)			
<i>ACLF</i> <sup>a</sup>										
Yes	37	11	(2–20)	<0.001	20 (54.1)	0.010	14 (35.1)	0.002		
No	122	3	(6–11)		36 (29.5)		13 (11.5)			
<i>CLIF-CAD</i> <sup>a</sup>										
≤45	18	3.0	(0–7)	0.001	1 (5.6)	0.007	0 (0.0)	0.080		
>45	163	8.0	(3–15)		61 (37.4)		28 (17.2)			
<i>SIRS</i> <sup>a</sup>										
<2	104	6.0	(3–12)	0.112	33 (31.7)	0.225	16 (15.4)	0.543		
≥2	55	8.0	(3–16)		23 (41.8)		8 (14.6)			
<i>qSOFA</i>										
<2	164	7.0	(3–13)	0.489	54 (32.9)	0.152	25 (15.2)	0.755		
≥2	22	8.5	(2–21)		11 (50.0)		4 (18.2)			
<i>qSOFA</i>										
0	87	6.0	(3–13)	0.134	26 (29.9)	0.136	11 (12.6)	0.673		
1	77	8.0	(3–13)		28 (36.4)		14 (18.2)			
2	20	11.5	(3–23)		11 (55.0)		4 (20.0)			
3	2	0.5	(0–1)		0 (0.0)		0 (0.0)			
<i>qSOFA-Na+</i> <sup>a</sup>										
<2	147	7.0	(1–11)	0.266	42 (28.6)	0.001	18 (12.2)	0.038		
≥2	37	8.0	(3–16)		22 (59.5)		10 (27.0)			
<b>Total</b>	<b>186</b>	<b>7.0</b>	<b>(3–14)</b>	<b>–</b>	<b>65 (35.0)</b>	<b>–</b>	<b>29 (15.6)</b>	<b>–</b>		

*qSOFA* quick sequential organ failure assessment, *ICU* intensive care unit, *SIRS* systemic inflammatory response syndrome, *MELD* model of end stage liver disease score  
<sup>a</sup>159 (85.5%)/159 (85.5%)/181 (97.3%)/165 (88.7%)/183 (98.9%) of the patients had sufficient data to calculate *ACLF/SIRS/CLIF-C AD/MELD* and *qSOFA-Na+*, respectively

have expected SIRS criteria to be a better predictor for outcome in our study than qSOFA. However, both scores attribute one point to a deranged respiratory function (increased rate of breathing). Patients suffering from decompensated liver cirrhosis do not usually exhibit similarly profound changes in respiratory rate as seen in sepsis; therefore it is possible that assessment of respiratory rate is not as valuable for detection of disease severity in patients with decompensated liver disease when compared to patients with sepsis. This might explain why neither qSOFA nor SIRS adequately discriminate between survivors and non-survivors in patients with decompensated liver cirrhosis.

A significant percentage of patients with decompensated liver cirrhosis suffer from hyponatraemia due to volume excess [24–26]. Hyponatraemia was linked to increased mortality in patients with decompensated liver cirrhosis in several studies [24–26] and a version of the MELD score incorporating sodium as an additional variable showed good predictive ability for outcome in patients with decompensated liver cirrhosis [46–48]. Sodium was shown to be an independent predictor for mortality in multivariate analysis in patients with liver disease [46, 47]. It was therefore tempting to create an extended qSOFA by adding a sodium component to the qSOFA score. Taking the presence of hyponatraemia


into account to calculate an extended qSOFA score increased its predictive performance with regard to ICU admission and in-hospital mortality. qSOFA-Na+ showed good specificity with a high negative predictive value for in-hospital mortality. However, sensitivity and overall accuracy remained poor. Thus, the extension of qSOFA by a sodium component may add only moderate diagnostic value in outcome prediction in patients with decompensated liver cirrhosis. However, validation is certainly warranted, especially as case numbers in our study were too small to evaluate lower sodium cut-offs. The extension of qSOFA with a disease-specific variable has been investigated by others [3, 7, 8, 49]. The addition of lactate levels to qSOFA did result in an increase in predictive power of qSOFA in patients with suspected infection [3, 7, 8]. However, this increase was only moderate as in our study.

Several others have evaluated an SOFA variation in patients with decompensated liver cirrhosis [50, 51]. A liver specific adaptation of SOFA score (CLIF-SOFA) showed the best AUC for in-hospital mortality when compared to MELD and SOFA in patients with acute on chronic liver disease [51]. A recently published study evaluated a new disease-specific variation of quick CLIF-SOFA including creatinine, bilirubin, INR and vasopressin levels as well a blood pressure criterion (mean arterial pressure below 70 mm Hg) [50]. This test showed good predictive power with respect to in-hospital mortality [50]. However, the calculation of CLIF-SOFA requires extensive laboratory work-up and is therefore not fit for bedside triage.


In conclusion, a disease-specific modification of qSOFA may result in the addition of diagnostic value. However, its usefulness should be further evaluated with careful evaluation of the respective components.

### Limitations

Our study is limited by several factors that appear mainly driven by study design. First, our study includes a relatively small sample of patients and therefore the



**Fig. 2** ▲ Comparison of qSOFA-Na+ with qSOFA to predict **a** in-hospital mortality, **b** ICU admission. *qSOFA* quick sequential organ failure assessment, *ICU* intensive care unit



**Fig. 3** ▲ Comparison of qSOFA-Na+ (different cut-offs) with qSOFA to predict **a** in-hospital mortality, **b** ICU admission. *qSOFA* quick sequential organ failure assessment, *ICU* intensive care unit

predictive value of qSOFA in patients with decompensated liver cirrhosis could have been missed. A significant percentage of available patients had to be excluded due to the lack of sufficient parameters to calculate qSOFA or incomplete records. Second, this is a retrospective database study; therefore interpretation of data is subject to bias. Third, the proportion of patients suffering from spontaneous bacterial peritonitis is lower in our study when compared to others [33, 34]. It is therefore possible that qSOFA might have predictive value in a population with a higher incidence of spontaneous bacterial peritonitis. Fourth, we only used sodium to extend qSOFA. Other param-

eters such as lactate levels or base excess as well as adaptations in the cut-off values of the qSOFA score might have more additional value to qSOFA than sodium levels. This should be subject to further investigation. Our study is further limited by our definition of acute on chronic liver failure, due to the retrospective study design with anonymisation of the primary data after data extraction, we were not able to assess for variables such as the grade of hepatic encephalopathy or the need for vasoactive agents to assess qSOFA in specific subgroups of liver failure.

## Conclusions

qSOFA does not predict in-hospital mortality, ICU admission or length of hospitalisation in patients with decompensated liver cirrhosis in our study. Unsurprisingly, the MELD score was the best already established scoring system to adequately predict in-hospital mortality in our patient collective. Interestingly, SIRS score was not associated with outcome in this study. The reasons therefore stay elusive. The extension of qSOFA with a disease-specific component, the qSOFA-Na+, significantly increased the predictive ability of qSOFA. The addition of specific disease makers to qSOFA

therefore seems tempting; however further validation is certainly needed.

## Corresponding address

### Dr. C. A. Pfortmueller

Department of Intensive Care, Inselspital, Bern University Hospital  
Freiburgstrasse 10, 3010 Bern, Switzerland  
carmen.pfortmueller@insel.ch

## Compliance with ethical guidelines

**Conflict of interest.** M. Müller, J. C. Schefold, A. B. Leichtle, D. Srivastava, G. Lindner, A. K. Exadaktylos and C. A. Pfortmueller declare that they have no competing interests.

The study was approved by the regional ethics committee of the Canton of Bern, Switzerland (KEK: 14-02-13). Individual informed consent was waived by the ethics committee.

## References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 315(8):801–810
2. Finkelsztajn EJ, Jones DS, Ma KC, Pabon MA, Delgado T, Nakahira K et al (2017) Comparison of qSOFA and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit. *Crit Care* 21(1):73
3. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A et al (2016) Assessment of clinical criteria for sepsis: For the third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 315(8):762–774
4. Churpek MM, Zdravcevic FJ, Winslow C, Howell MD, Edelson DP (2015) Incidence and prognostic value of the systemic inflammatory response syndrome and organ dysfunctions in ward patients. *Am J Respir Crit Care Med* 192(8):958–964
5. Quinten VM, van Meurs M, Wolffensperger AE, Ter Maaten JC, Ligtenberg JJM (2017) Sepsis patients in the emergency department: Stratification using the Clinical Impression Score, Predisposition, Infection, Response and Organ dysfunction score or quick Sequential Organ Failure Assessment score? *Eur J Emerg Med*. <https://doi.org/10.1097/MEJ.0000000000000460>
6. Kim M, Ahn S, Kim WY, Sohn CH, Seo DW, Lee YS et al (2017) Predictive performance of the quick Sequential Organ Failure Assessment score as a screening tool for sepsis, mortality, and intensive care unit admission in patients with febrile neutropenia. *Support Care Cancer* 25(5):1557–1562
7. Henning DJ, Puskarich MA, Self WH, Howell MD, Donnino MW, Yealy DM et al (2017) An emergency department validation of the SEP-3 sepsis and septic shock definitions and comparison with 1992 consensus definitions. *Ann Emerg Med* 70(4):544–552.e5. <https://doi.org/10.1016/j.annemergmed.2017.01.008>
8. Ho KM, Lan NS (2017) Combining quick sequential organ failure assessment with plasma lactate concentration is comparable to standard sequential organ failure assessment score in predicting mortality of patients with and without suspected infection. *J Crit Care* 38:1–5
9. Donnelly JP, Safford MM, Shapiro NI, Baddley JW, Wang HE (2017) Application of the third international consensus definitions for sepsis (Sepsis-3) classification: A retrospective population-based cohort study. *Lancet Infect Dis* 17(6):661–670. [https://doi.org/10.1016/S1473-3099\(17\)30117-2](https://doi.org/10.1016/S1473-3099(17)30117-2)
10. Freund Y, Lemachatti N, Krastinova E, Van Laer M, Claessens YE, Avondo A et al (2017) Prognostic accuracy of Sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department. *JAMA* 317(3):301–308
11. Williams JM, Greenslade JH, McKenzie JV, Chu K, Brown AF, Lipman J (2017) Systemic inflammatory response syndrome, quick sequential organ function assessment, and organ dysfunction: Insights from a prospective database of ED patients with infection. *Chest* 151(3):586–596
12. Wang JY, Chen YX, Guo SB, Mei X, Yang P (2016) Predictive performance of quick sepsis-related organ failure assessment for mortality and ICU admission in patients with infection at the ED. *Am J Emerg Med* 34(9):1788–1793
13. Chen YX, Wang JY, Guo SB (2016) Use of CRB-65 and quick sepsis-related organ failure assessment to predict site of care and mortality in pneumonia patients in the emergency department: A retrospective study. *Crit Care (Lond)* 20(1):167
14. Singer AJ, Ng J, Thode HC Jr., Spiegel R, Weingart S (2017) Quick SOFA scores predict mortality in adult emergency department patients with and without suspected infection. *Ann Emerg Med* 69(4):475–479
15. Murray CJ, Atkinson C, Bhalla K, Birbeck G, Burstein R, Chou D et al (2013) The state of US health, 1990–2010: Burden of diseases, injuries, and risk factors. *JAMA* 310(6):591–608
16. Mokdad AA, Lopez AD, Shahrzaz S, Lozano R, Mokdad AH, Stanaway J et al (2014) Liver cirrhosis mortality in 187 countries between 1980 and 2010: A systematic analysis. *Bmc Med* 12:145
17. Mathur AK, Chakrabarti AK, Mellinger JL, Volk ML, Day R, Singer AL et al (2017) Hospital resource intensity and cirrhosis mortality in United States. *World J Gastroenterol* 23(10):1857–1865
18. Alsultan MA, Alhrshed RS, Aljumah AA, Baharoon SA, Arabi YM, Aldawood AS (2011) In-hospital mortality among a cohort of cirrhotic patients admitted to a tertiary hospital. *Saudi J Gastroenterol* 17(6):387–390
19. Koch A, Trautwein C, Tacke F (2017) Acute liver failure. *Med Klin Intensivmed Notfmed* 112(4):371–381
20. Al-Hamoudi WK (2010) Cardiovascular changes in cirrhosis: Pathogenesis and clinical implications. *Saudi J Gastroenterol* 16(3):145–153
21. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT (2002) Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. *Hepatology* 35(3):716–721
22. Pfortmueller CA, Wiemann C, Funk GC, Leichtle AB, Fiedler GM, Exadaktylos AK et al (2014) Hypoglycemia is associated with increased mortality in patients with acute decompensated liver cirrhosis. *J Crit Care* 29(2):316.e7–316.e12
23. CLIF-C (2017) AD (Acute Decompensation) score and expected mortality rates 2017. <https://www.clifresearch.com/ToolsCalculators.aspx>
24. Morales BP, Planas R, Bartoli R, Morillas RM, Sala M, Cabre E et al (2017) Early hospital readmission in decompensated cirrhosis: Incidence, impact on mortality, and predictive factors. *Dig Liver Dis* 49(8):903–909. <https://doi.org/10.1016/j.dld.2017.03.005>
25. Barakat AA, Metwaly AA, Nasr FM, El-Ghannam M, El-Talkawy MD, Taleb HA (2015) Impact of hyponatremia on frequency of complications in patients with decompensated liver cirrhosis. *Electron Physician* 7(6):1349–1358
26. Moller S, Krag A, Bendtsen F (2014) Kidney injury in cirrhosis: Pathophysiological and therapeutic aspects of hepatorenal syndromes. *Liver Int* 34(8):1153–1163
27. Arroyo V, Jalan R (2016) Acute-on-chronic liver failure: Definition, diagnosis, and clinical characteristics. *Semin Liver Dis* 36(2):109–116
28. Jalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Gines P et al (2014) Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. *J Hepatol* 61(5):1038–1047
29. Jalan R, Pavesi M, Saliba F, Amoros A, Fernandez J, Holland-Fischer P et al (2015) The CLIF Consortium Acute Decompensation score (CLIF-C ADS) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. *J Hepatol* 62(4):831–840
30. Li N, Huang C, Yu KK, Lu Q, Shi GF, Zheng JM (2017) Validation of prognostic scores to predict short-term mortality in patients with HBV-related acute-on-chronic liver failure: The CLIF-C OF is superior to MELD, CLIF SOFA, and CLIF-C ACLF. *Medicine (Baltimore)* 96(17):e6802
31. DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. *Biometrics* 44(3):837–845
32. Forward E, Konecny P, Burston J, Adhikari S, Doolan H, Jensen T (2017) Predictive validity of the qSOFA criteria for sepsis in non-ICU inpatients. *Intensive Care Med* 43(6):945–946. <https://doi.org/10.1007/s00134-017-4776-2>
33. Oladimeji AA, Temi AP, Adekunle AE, Taiwo RH, Ayokunle DS (2013) Prevalence of spontaneous bacterial peritonitis in liver cirrhosis with ascites. *Pan Afr Med J* 15:128
34. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B et al (2000) Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: A consensus document. *International Ascites Club. J Hepatol* 32(1):142–153
35. Antunes AG, Teixeira C, Vaz AM, Martins C, Queiros P, Alves A et al (2017) Comparison of the prognostic value of Chronic Liver Failure Consortium scores and traditional models for predicting mortality in patients with cirrhosis. *Gastroenterol Hepatol* 40(4):276–285
36. Zubieta-Rodriguez R, Gomez-Correa J, Rodriguez-Amaya R, Ariza-Mejia KA, Tolozza-Cuta NA (2017) In-hospital mortality in cirrhotic patients at a tertiary care center. *Rev Gastroenterol Mex* 82(3):203–209. <https://doi.org/10.1016/j.rgmx.2016.10.002>
37. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P et al (2003) Model for end-stage liver disease (MELD) and allocation of donor livers. *Gastroenterology* 124(1):91–96
38. Lyles T, Elliott A, Rockey DC (2014) A risk scoring system to predict in-hospital mortality



## Veranstaltungstipp



© NicoElnino / Getty Images / iStock

- in patients with cirrhosis presenting with upper gastrointestinal bleeding. *J Clin Gastroenterol* 48(8):712–720
39. Balekian AA, Gould MK (2012) Predicting in-hospital mortality among critically ill patients with end-stage liver disease. *J Crit Care* 27(6):740 e1–740 e7
40. Innocenti F, Tozzi C, Donnini C, De Villa E, Conti A, Zanobetti M et al (2017) SOFA score in septic patients: incremental prognostic value over age, comorbidities, and parameters of sepsis severity. *Intern Emerg Med* 13(3):405–412. <https://doi.org/10.1007/s11739-017-1629-5>
41. Das K, Das K, Datta S, Pal S, Hembram JR, Dhali GK et al (2010) Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis. *Liver Int* 30(7):1033–1042
42. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F (2009) The systemic inflammatory response syndrome in cirrhotic patients: Relationship with their in-hospital outcome. *J Hepatol* 51(3):475–482
43. Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E et al (2007) Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. *Hepatology* 46(6):1872–1882
44. Piano S, Bartoletti M, Tonon M, Baldassarre M, Chies G, Romano A et al (2017) Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. *Gut*. pii: gutjnl-2017-314324. <https://doi.org/10.1136/gutjnl-2017-314324>
45. Raith EP, Udy AA, Bailey M, McGloughlin S, MacIsaac C, Bellomo R et al (2017) Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. *JAMA* 317(3):290–300
46. Chen RC, Wang XD, Dong JZ, Lin Z, Wu JM, Cai YJ et al (2017) A MELD-based nomogram for predicting 3-month mortality of patients with acute-on-chronic hepatitis B liver failure. *Clin Chim Acta* 468:195–200
47. Shi KQ, Cai YJ, Lin Z, Dong JZ, Wu JM, Wang XD et al (2017) Development and validation of a prognostic nomogram for acute-on-chronic hepatitis B liver failure. *J Gastroenterol Hepatol* 32(2):497–505
48. Cai YJ, Dong JJ, Dong JZ, Chen Y, Lin Z, Song M et al (2017) A nomogram for predicting prognostic value of inflammatory response biomarkers in decompensated cirrhotic patients without acute-on-chronic liver failure. *Aliment Pharmacol Ther* 45(11):1413–1426
49. French-O'Carroll R, Frohlich S, Murphy N, Conlon N (2015) Predictors of outcome in decompensated liver disease: Validation of the SOFA-L score. *Ir Med J* 108(4):114–116
50. Zhou XD, Zhang JY, Liu WY, Wu SJ, Shi KQ, Braddock M et al (2017) Quick chronic liver failure-sequential organ failure assessment: An easy-to-use scoring model for predicting mortality risk in critically ill cirrhosis patients. *Eur J Gastroenterol Hepatol* 29(6):698–705
51. Sy E, Ronco JJ, Searle R, Karvellas CJ (2016) Prognostication of critically ill patients with acute-on-chronic liver failure using the chronic liver failure-sequential organ failure assessment: A Canadian retrospective study. *J Crit Care* 36:234–239

### Faire Bedingungen für integrierte Versorgungsformen

16. DGIV-Bundeskongress, 26. November 2019

Mit den Initiativen für das „Faire-Kassenwahl-Gesetz“ wurde der Fairness-Begriff in die aktuelle gesundheitspolitische Diskussion eingebracht. Der Bundeskongress 2019 der Deutschen Gesellschaft für Integrierte Versorgung im Gesundheitswesen e.V. (DGIV) greift das auf, indem er ganz aktuell die Frage nach fairen wettbewerblichen Bedingungen im Schnittstellenbereich von ambulant und stationär stellt. Vertreter von Politik, Selbstverwaltung und Versorgungsforschung werden sich mit folgenden Themen auseinandersetzen:

- Anforderungen an einen einheitlichen Ordnungsrahmen im Schnittstellenbereich von ambulant und stationär
- Weiterentwicklung der Bedarfsplanung bei der Versorgung in den Regionen
- Vorschläge für ein modernes Vergütungssystem
- Perspektiven für die sektorenübergreifende Versorgung
- Digitalisierung des Gesundheitswesens – die Roadmap der Bundesregierung

Weitere Informationen zum Programm und Anmeldeformular finden Sie unter [www.dgiv.org](http://www.dgiv.org)

**DGIV**

Deutsche Gesellschaft für Integrierte Versorgung im Gesundheitswesen e.V.

**Veranstalter:** DGIV e.V., Friedrichstraße 171, 10117 Berlin, Tel.: 030/44727080, Fax: 030/44729746, E-Mail: [info@dgiv.org](mailto:info@dgiv.org)

#### Wissenschaftliche Leitung

Prof. Dr. Stefan G. Spitzer, Dresden  
Prof. Dr. Dr. Alfred Holzgreve, Berlin  
Dr. Michael Meyer, Berlin

**Tagungsort:** Hotel Aquino, Tagungszentrum Katholische Akademie Hannoversche Straße 5b, 10115 Berlin-Mitte

#### DGIV-Fachdiskussion am 25. November 2019, 18 bis 21 Uhr

*Ein dritter Versorgungsbereich – Zwischenschritt zur echten integrierten Versorgung?*

SpiFa, KBV, Bund/Länder-AG, Notfallversorgung – die Konzepte häufen sich, in denen ein dritter Versorgungsbereich zwischen ambulant und stationär mehr oder minder konkrete Ausgestaltung erfährt, um die Sektorengrenze zu überwinden. Die DGIV e.V. sieht in diesen unterschiedlichen Konzepten interessante Ansätze, um zu echten integrierten Versorgungslösungen kommen zu können. Wie aber könnten die vorliegenden Konzepte weitergedacht werden, zu einem Versorgungs- und Vergütungssystem ohne Sektorengrenzen zu kommen? Dieser Frage widmet sich die Fachdiskussion am Vorabend des DGIV-Bundeskongresses.

**Veranstaltungsort:** Hauptstadtbüro der Siemens Healthineers AG, Friedrichstr. 133, 10117 Berlin

**Quelle und weitere Infos:** [www.dgiv.org](http://www.dgiv.org)